Curasight can resume enrolment in its phase I glioblastoma trial after regulators gave the go ahead for an amended protocol. With dosing back under way, the company holds to its timeline for topline data in H1 2027.
Read the full article at biostock.se:
Curasight continues its glioblastoma trial following approval of updated protocol
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/